Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 7,056 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer, Breast Neoplasms Clear all
Recruiting No phase listed Observational

Genomic Services Research Program

NCT02595957
View directory record Official record
Conditions
Colon Cancer, Breast Cancer
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 105 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2099
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 3:09 PM EDT
Not yet recruiting Phase 2 Interventional

EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction)

NCT07883512
View directory record Official record
Conditions
Breast Cancer, Supportive Care in Cancer
Interventions
Empagliflozin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 3:09 PM EDT
Completed Not applicable Interventional

Feasibility of Providing a Purpose Renewal Intervention for Cancer Survivors Via Virtual Groups

NCT04767464
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm
Interventions
Compass Course
Other
Lead sponsor
Mary Radomski
Other
Eligibility
25 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 20, 2026, 3:09 PM EDT
Completed No phase listed Observational

Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer

NCT00303914
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Pain, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
assessment of therapy complications, cognitive assessment, psychosocial assessment and care
Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
2,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
32
States / cities
Chicago, Illinois • Evanston, Illinois • Elkhart, Indiana + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 20, 2026, 3:09 PM EDT
Terminated No phase listed Observational

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

NCT04106167
View directory record Official record
Conditions
Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
Interventions
Allogeneic natural killer (NK) cell
Genetic
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 20, 2026, 3:09 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)

NCT01984892
View directory record Official record
Conditions
Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin, Basal Cell Cancer of the Skin, Breast Cancer
Interventions
Poly-ICLC
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
14 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 3:09 PM EDT
Recruiting Phase 1 Interventional

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

NCT06778863
View directory record Official record
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Bladder Cancer
Interventions
CLSP-1025
Drug
Lead sponsor
Clasp Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 20, 2026, 3:09 PM EDT
Completed Phase 1 Interventional

Clinical Trial of Trametes Versicolor in Women With Breast Cancer

NCT00680667
View directory record Official record
Conditions
Breast Cancer
Interventions
Coriolus versicolor extract
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota • Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 20, 2026, 3:09 PM EDT
Active, not recruiting Phase 2 Interventional Results available

PhII ICb With/Without Erbitux in MBC Pts

NCT00248287
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Irinotecan + Carboplatin, irinotecan + Carboplatin + erbitux
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2026
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 20, 2026, 3:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

NCT00182767
View directory record Official record
Conditions
Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
ixabepilone, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
5
States / cities
Farmington, Connecticut • Albany, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 20, 2026, 3:09 PM EDT
Completed Not applicable Interventional

Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer

NCT04493034
View directory record Official record
Conditions
Breast Cancer
Interventions
Art Therapy, Music Therapy
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 20, 2026, 3:09 PM EDT
Completed Phase 1 Interventional

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

NCT03471663
View directory record Official record
Conditions
Breast Cancer
Interventions
D-0502, palbociclib
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
11
States / cities
Fresno, California • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 20, 2026, 3:09 PM EDT
Recruiting No phase listed Observational

Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning

NCT07023887
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
6-12-25 Training Regimen, 8x8 Training Regimen, 5/5/5 Cluster Set Training Regimen, Double Training Regimen
Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
20 Years to 89 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 3:09 PM EDT
Completed Phase 2 Interventional

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

NCT02130700
View directory record Official record
Conditions
Prostate Cancer
Interventions
VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles
Drug
Lead sponsor
Innocrin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 20, 2026, 3:09 PM EDT
Completed Not applicable Interventional

Effect of Aromatase Inhibitors on Bones and Genes

NCT00603967
View directory record Official record
Conditions
Breast Cancer, Postmenopausal
Interventions
Dual x-ray absorptiometry (DXA), Blood draw, Questionnaire
Procedure · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older · Female only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 20, 2026, 3:09 PM EDT
Recruiting Phase 2 Interventional

A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer

NCT07768436
View directory record Official record
Conditions
Adenocarcinoma of the Breast, Breast Cancer, Triple Negative Breast Cancer
Interventions
CMF Regimen, Paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
70 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 20, 2026, 3:09 PM EDT
Terminated Phase 2 Interventional Results available

Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery

NCT01234532
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Triple-negative Breast Cancer
Interventions
entinostat, anastrozole, diagnostic laboratory biomarker analysis, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 20, 2026, 3:09 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

NCT00817362
View directory record Official record
Conditions
Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Cancer of the Breast
Interventions
IPI-504, Trastuzumab
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Palm Springs, California • Boca Raton, Florida • Davie, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 20, 2026, 3:09 PM EDT
Not yet recruiting Not applicable Interventional

Feasibility and Effectiveness of Sentinel Lymph Node Biopsy in Inflammatory Breast Cancer

NCT07876986
View directory record Official record
Conditions
Breast Cancer
Interventions
Sentinel node biopsy with blue dye and radioisotope
Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 3:09 PM EDT
Recruiting Phase 2 Interventional

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

NCT04771520
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Primary Malignant Central Nervous System Neoplasm, Locally Advanced Sarcoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Primary Malignant Central Nervous System Neoplasm, Metastatic Sarcoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Avapritinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 20, 2026, 3:09 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

NCT02315196
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions
pegylated liposomal doxorubicin hydrochloride, epirubicin hydrochloride, carboplatin, therapeutic conventional surgery, paclitaxel, laboratory biomarker analysis, quality-of-life assessment
Drug · Procedure · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2041
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 20, 2026, 3:09 PM EDT
Active, not recruiting Not applicable Interventional

Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer

NCT01802346
View directory record Official record
Conditions
Breast Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Interventions
dietary intervention, nutritional support, laboratory biomarker analysis
Dietary Supplement · Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
19 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Newport Beach, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 20, 2026, 3:09 PM EDT
Recruiting Not applicable Interventional

The MIND-BC Study: MIND Diet for Breast Cancer Cognition

NCT07018986
View directory record Official record
Conditions
Breast Cancer
Interventions
MIND Diet, Usual Diet
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 20, 2026, 3:09 PM EDT
Terminated Phase 2 Interventional Results available

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

NCT00602446
View directory record Official record
Conditions
Breast Cancer, Iron Overload, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer
Interventions
deferasirox
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 20, 2026, 3:09 PM EDT